TNF and Opportunistic infection: Despite upadacitinib’s promising results for those resistant to TNF-α inhibitors, it has adverse effects and may want to be avoided in those susceptible to anemia, neutropenia, elevated creatine kinase levels, hepatic issues, malignancies, thrombus development, and serious or opportunistic infections [10,20].